MedTrace Logo

Mental Ability Challenge Study in Adults With and Without HIV

NCT03244488 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2019-02-25

No results posted yet for this study

Summary

It is estimated that by 2016, nearly 50% of HIV-positive individuals in the US will be aged 50 or older, and up to 60% of those will experience some degree of cognitive impairment as they age. The purpose of this study is to evaluate the contribution of the neuronal cholinergic receptor system to the cognitive impairments seen in adults aging with chronic HIV Infection. By using anti-cholinergic challenge drugs to reversibly "stress" cognitive functioning, the investigators hope to understand whether the presence of the HIV virus in the brain impairs the neural system necessary for normal cognition, more than would be expected from normal cognitive aging.

Conditions

Interventions

DRUG

Scopolamine Injectable Product

2.5 or 5 mcg/kg of scopolamine via IV

DRUG

Mecamylamine Pill

10 or 20mg of mecamylamine orally

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-12-31
Completion
2018-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03244488 on ClinicalTrials.gov